Adjuvant chemotherapy intensity and prognosis in completely resected high-grade neuroendocrine lung carcinoma: a post hoc analysis of JCOG1205/1206.
Tetsuya Isaka, Hirotsugu Kenmotsu, Masashi Wakabayashi et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of the phase III JCOG1205/1206 trial evaluated the impact of adjuvant chemotherapy intensity on prognosis in 217 patients with completely resected high-grade neuroendocrine lung carcinoma. The study found that higher relative dose intensity (RDI) in the etoposide plus cisplatin (EP) regimen was associated with worse five-year relapse-free survival (RFS), indicating that high-intensity chemotherapy may not improve outcomes.
Key findings
- Treatment completion rate was higher in the EP group at 89.0% compared to 74.1% in the IP group (P = 0.0046).
- Five-year RFS was 66.0% for EP patients who completed treatment versus 73.3% for those who did not.
- RDI ≥90% was linked to worse RFS in the EP arm (HR, 2.024; 95% CI, 1.081-3.787).
- No significant associations were found for RDI in the IP arm.
Why it matters
Understanding the relationship between chemotherapy intensity and prognosis in high-grade neuroendocrine lung carcinoma can guide treatment decisions. This study suggests that maximizing chemotherapy intensity may not yield better outcomes, prompting a reevaluation of treatment strategies.